Disease-modifying Therapies for Multiple Sclerosis (Q48411692)

11 February 2018

title

Disease-modifying Therapies for Multiple Sclerosis (English)

1 reference

11 February 2018

0 references

John R. Corboy

1

1 reference

11 February 2018

Douglas S. Goodin

series ordinal

2

1 reference

11 February 2018

Elliot M. Frohman

series ordinal

3

1 reference

11 February 2018

publication date

1 January 2003

1 reference

11 February 2018

Current treatment options in neurology

published in

1 reference

11 February 2018

volume

5

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

35-54

1 reference

11 February 2018

Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Cerebral magnetic resonance imaging findings in multiple sclerosis. Relation to disturbance of affect, drive, and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Multisequence MRI in clinically isolated syndromes and the early development of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-003-0021-0

Revised estimate of the prevalence of multiple sclerosis in the united states

21 January 2018

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis

1 reference

12 December 2020

The accuracy of magnetic resonance imaging in patients with suspected multiple sclerosis. The Rochester-Toronto Magnetic Resonance Imaging Study Group

1 reference

12 December 2020

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

12 December 2020

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

1 reference

12 December 2020

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

The economics of multiple sclerosis. Distribution of costs and relationship to disease severity

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

1 reference

12 December 2020

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates

1 reference

12 December 2020

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

12 December 2020

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS.

1 reference

12 December 2020

Imaging axonal damage of normal-appearing white matter in multiple sclerosis

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

Magnetic resonance imaging in clinically isolated lesions of the brain stem

1 reference

12 December 2020

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

1 reference

12 December 2020

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Axonal Transection in the Lesions of Multiple Sclerosis

1 reference

12 December 2020

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT

1 reference

12 December 2020

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

12 December 2020

A magnetization transfer histogram study of normal-appearing brain tissue in MS

1 reference

12 December 2020

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

1 reference

12 December 2020

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

12 December 2020

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation

1 reference

12 December 2020

Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden

1 reference

12 December 2020

Optic neuritis: A population-based study in Olrnsted County, Minnesota

1 reference

12 December 2020

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

1 reference

12 December 2020

The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis

1 reference

12 December 2020

10.1007/S11940-003-0021-0

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018